Maitake Grifola frondosa (Dicks.) Gray
Also called: hen of the woods, dancing mushroom, king of mushrooms, cloud mushroom
Maitake, Grifola frondosa, is an edible mushroom eaten widely in Asia and used in traditional medicine for diabetes and high blood pressure. Supplements are extracts; research has focused on polysaccharide fractions such as maitake D-fraction.
- Category
- Mushroom
- Forms
- Mushroom (food); polysaccharide extracts such as D-fraction
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-28
Class 2 Moderately studied in people. This entry cites 3 RCTs of maitake alone: source [4] (maitake bread versus placebo bread, 47 older adults), source [7] (capsules of maitake D-fraction, a proteoglycan extract, versus placebo, 141 patients) and source [8] (extract versus clomiphene, 72 women with PCOS, open-label). [4]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBrain, mood and sleep1 topic
CImmune system and infection1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Immune measures in breast cancer survivors | C | Phase I/II trial in 34 postmenopausal women free of disease: a liquid extract (0.1–5 mg/kg twice daily, 3 weeks) both raised and lowered different immune measures, with non-monotonic dose responses. [2] |
| Immune cell function in myelodysplastic syndromes | C | Phase II study (21 enrolled, 18 evaluable): 3 mg/kg twice daily for 12 weeks increased neutrophil and monocyte function in laboratory tests; there was no placebo group. [3] |
| Cognitive function in healthy older adults | C | RCT in 47 Japanese adults aged 60 or older: bread with 50 g of one maitake strain for 18 weeks improved MoCA-J scores versus placebo; a second strain showed no difference. [4] |
| Side effects of chemoradiotherapy in head and neck cancer | C | A randomized placebo-controlled trial in 141 patients reported that maitake D-fraction capsules taken during chemoradiotherapy reduced severe treatment-related adverse events and improved quality-of-life scores in advanced laryngeal and pharyngeal cancers. [7] |
Main constituents: Beta-1,6-glucan, a protein-bound polysaccharide identified as the active constituent; alpha-glucan [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Liquid extract 0.1, 0.5, 1.5, 3 or 5 mg/kg twice daily for 3 weeks (breast cancer phase I/II trial). [2]
- Extract 3 mg/kg twice daily for 12 weeks (myelodysplastic syndromes). [3]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines2 listed
Warfarin; Hypoglycemic (blood glucose-lowering) medications
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Asymptomatic eosinophilia occurred in 4 of 18 evaluable patients in the myelodysplastic syndromes study. [3]
- Two of 34 women withdrew for grade 1 possibly related effects: nausea and joint swelling in one, rash and itching in the other. [2]
- Because some doses lowered immune measures, the authors cautioned that maitake may depress as well as enhance immune function. [2]
Interactions
| With | What happens |
|---|---|
| Warfarin | A case report suggests maitake can interact with warfarin, raising the INR. [1] |
| Diabetes medications | Maitake may increase their effects in people with type 2 diabetes and can lower blood glucose. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Index Fungorum lists Grifola frondosa (Dicks.) Gray as the current name. [5]
Regulatory status
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 1 entry naming maitake: NDI 1310, a maitake powder (submitted 2023-10-03). No entry names Grifola frondosa. Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Warfarin: A case report suggests maitake can interact with warfarin, resulting in INR elevation. [P1]
- Hypoglycemic (blood glucose-lowering) medications: Maitake may increase their effects in people with type 2 diabetes; the source notes maitake may not be appropriate for people taking these medications because of possible synergistic effects. [P1]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- Fochi et al. 2022: morphological identification of Grifola frondosa is not feasible in formulated food supplements; a species-specific LAMP DNA assay (detection down to 0.62 pg genomic DNA, ten related fungal species negative) confirmed maitake in the commercial supplements tested except one, revealing a mislabeling (or a food fraud). [P2]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination of each component that is a dietary ingredient, before use — Required by 21 CFR 111.75(a)(1)(i); a manufacturer may petition for an exemption from this testing under 111.75(a)(1)(ii). [P6]
- DNA-based identity of Grifola frondosa (e.g. species-specific LAMP assay) — Morphological identification is not feasible in formulated supplements, and one commercial product tested in a 2022 study did not contain maitake. [P2]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Memorial Sloan Kettering Cancer Center. About Herbs: Maitake (last updated July 9, 2026), 2026-07-09. mskcc.org
- Fochi V, et al. A rapid and efficient loop-mediated isothermal amplification (LAMP) assay for the authentication of food supplements based on maitake (Grifola frondosa). Food Anal Methods 2022;15(7):1803-1815 (PMID 35282313), 2022-03-08. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (accessed October 29, 2026), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR) list (accessed October 29, 2026), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75 (title 21 displayed up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- Memorial Sloan Kettering Cancer Center. About Herbs: Maitake (last updated July 9, 2026), 2026-07-09. mskcc.org
- Deng G, et al. A phase I/II trial of a polysaccharide extract from Grifola frondosa (maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol 2009;135(9):1215-21, 2009-09. pubmed.ncbi.nlm.nih.gov
- Wesa KM, et al. Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study. Cancer Immunol Immunother 2015;64(2):237-47, 2015-02. pubmed.ncbi.nlm.nih.gov
- Jogi EM, et al. Maitake mushroom (Grifola frondosa) enhances cognitive function in healthy older Japanese: a randomized, double-blind, placebo-controlled trial. J Nutr Sci Vitaminol (Tokyo) 2026;72(2):163-175, 2026. pubmed.ncbi.nlm.nih.gov
- Index Fungorum. Grifola frondosa (Dicks.) Gray, record 362177 (accessed October 28, 2026). indexfungorum.org
- National Cancer Institute. Medicinal Mushrooms (PDQ®)–Health Professional Version (latest update 11/06/2024), 2024-11-06. cancer.gov
- Hu Q, Xie B. Effect of Maitake D-fraction in advanced laryngeal and pharyngeal cancers during concurrent chemoradiotherapy: a randomized clinical trial. Acta Biochim Pol 2022;69(3):625-632 (PMID 36070433), 2022-09-07. pubmed.ncbi.nlm.nih.gov
- Chen JT, et al. Maitake mushroom (Grifola frondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate. J Altern Complement Med 2010;16(12):1295-9 (PMID 21034160), 2010-12. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in mushroom: Chaga · Cordyceps · Lion's mane · Reishi · Shiitake · Turkey tail · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.